Tuesday, 4 July 2017

Hepatitis Hherapeutics Market Growth Is Expected To Reach USD 25.8 Billion By 2025

The key factors driving market growth include the rising number of infected population, growing consumption of alcohol & drugs, increase in global geriatric population, and improvement in access to hepatitis medicines.

Hepatitis is generally classified into two types based on the duration for which the patient suffers. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis.The population at a greater risk of hepatitis include people with HIV infection & HCV-infected sexual partners, who inject drugs & use intranasal drugs, recipients of infected blood products, and other population groups who live in unhygienic conditions.
According to the WHO, globally around 400 million people are infected with at least one form of hepatitis and every year nearly 1.4 people die due to the condition. Various government and private agencies are actively involved in the vaccination drive to prevent hepatitis. Hepatitis C leads to more serious complications compared to hepatitis A and B. As per WHO estimates, nearly 150 million are impacted by hepatitis C infection globally. Moreover, a significant number of hepatitis C patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.
View summary of this report, Click Here 
Further Key Findings From the Report Suggest:
  • Due to very high prevalence of target disease coupled with subsequent increase in the treatment rate Hepatitis C accounted for the majority market share of 75.6% in 2016
  • In 2016, North America held the largest share of nearly 42.9%. The key factors attributed to the regions high share include high patient awareness levels and the presence of advanced healthcare infrastructure. 
  • Asia Pacific is anticipated to witness the maximum growth with a CAGR of 5.8% over the forecast period. High economic development coupled with rapidly increasing healthcare expenditure are amongst key factors attributing to the regions high growth rate.
  • Key players include Gilead, Merck & Co. Inc., Johnson & Johnson, Bristol-Myers Squibb Company, and AbbVie Inc.
Click Here For Access Full Report : https://goo.gl/GC3LgV

Monday, 3 July 2017

Live Cell Imaging Market Worth Is Expected To Reach USD 9.0 Billion By 2025

Rising popularity of kinetic research over fixed cellular analysis is the key driver. Addition of dyes and reagents alter the cell behavior, mostly in a negative manner, which does not showcase the natural course of action of the cellular functions. Understanding the cellular behavior in its natural state is crucial in drug discovery and targeted drug therapy. This, in turn, increases the need for live cell imaging, thus boosting the market.

In a survey by Drug Discovery World Spring, almost 21% researchers prefer & use live cell imaging and 31% plan to use it in the future. Moreover, 38% of the respondents were interested in using live cell kinetic HCS imaging in the future. The most important feature for researchers is the ability to automate the incubation and image capturing of any live cell analyzer. Secondly, they also give importance to viable cell-tracking ability of the equipment. Further development in the technology of equipment is expected to fulfill these criteria and boost the utility of the same over the forecast period.
Development in delivering probes in living cells, targeting organelles, and proteins using some of the techniques has increased use and adoption of live cell imaging in research and other applications. With improved fluorescent probes, the techniques such as Fluorescence Resonance Energy Transfer (FRET) share a majority of the share.
View summary of this report, Click Here 
Further Key Findings From The Report Suggest:
  • Equipment dominated the product segment in 2016. The current system, although of great potential are still expected to perform better over the next few years. The general trend is to make the instruments compact and integrated for end-to-end processing.
  • Cell biology dominated the application with more than 30% of the shares and was closely followed by developmental biology. Stem cell and drug discovery are the upcoming fields to apply live cell imaging in the research.
  • North America dominated due to its high investment rate and technologically sound infrastructure. The research firms present in this region are technologically aware, hence, readily invest in high cost equipment.
  • Asia Pacific is expected to show fastest growth over the forecast period due to increasing application of these imaging techniques in drug discovery and personalized medicine.
  • Key players includes Carl Zeiss Meditec AG; Leica Microsystems; Nikon Corporation; Becton, Dickinson and Company; GE Healthcare; Olympus Corporation; Thermo Fisher Scientific Inc.; Sigma-Aldrich Corporation; PerkinElmer, Inc.; and Molecular Devices, LLC
Click Here For Access Full Report : https://goo.gl/meRSGy

Wednesday, 28 June 2017

Nanomedicine Market Worth Is Anticipated To Reach USD 350.8 Billion By 2025

Development of novel nanotechnology-based drugs and therapies is driven by the need to develop therapies that have fewer side effects and that are more cost-effective than traditional therapies, in particular for cancer.
Application of nanotechnology-based contrast reagents for diagnosis and monitoring of the effects of drugs on an unprecedented short timescale is also attributive drive growth in the coming years. Additionally, demand for biodegradable implants with longer lifetimes that enable tissue restoration is anticipated to influence demand.

As per the WHO factsheet, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million cancer-related deaths. Thus, demand for nanomedicine in order to curb such high incidence rate is expected to boost market progress during the forecast period.
Solutions such as nanoformulations with triggered release for tailor-made pharmacokinetics, nanoparticles for local control of tumor in combination with radiotherapy, and functionalized nanoparticles for targeted in-vivo activation of stem cell production are anticipated to drive R&D, consequently resulting in revenue generation in the coming years.
Biopharmaceutical and medical devices companies are actively engaged in development of novel products as demonstrated by the increasingly growing partnerships between leading enterprises and nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk signed a global collaboration and a licensing agreement for development and discovery of innovative drugs with multi-specific nanobodies. This strategic partnership is anticipated to rise the net annual sales of the products uplifting the market growth.
However, in contrary with the applications of nanotechnology, the entire process of lab to market approval is a tedious and expensive one with stringent regulatory evaluation involved thereby leading investors to remain hesitant for investments.
View summary of this report, Click Here 
Further key findings from the report suggest:
  • Therapeutics accounted for the largest share of market revenue in 2016 owing to presence of nanoemulsions, nanoformulations, or nanodevices
  • These devices possess the ability to cross biological barriers. Moreover, presence of drugs such as Doxil, Abraxane, and Emend is attributive for higher revenue generation
  • Presence of substantial number of products manufactured through the use of microbial sources can be attributed for the largest share
  • In-vitro diagnostics is expected to witness lucrative progress as a result of R&D carried out in this segment
  • Introduction of nano-enabled biomarkers, vectors and contrast agents with high-specificity and sensitivity are attributive for projected progress
  • Clinical cardiology is expected to witness the fastest growth through to 2025 owing to development in nano-functionalization and modification of surfaces for increased biocompatibility of implants in treatment of late thrombosis
  • Moreover, an abundance of research publications and patent filings from European region with a share of about 25% in nanomedicine-related publications is supportive for revenue generation from European economies
  • Asia Pacific is estimated to witness the fastest growth over the forecast period
  • Factors responsible include government and regulatory authorities that have implemented a framework to encourage R&D collaborations and framework extension.
  • Key players operating in this industry include Pfizer Inc., Ablynx NV, Nanotherapeutics Inc., Nanoviricides Inc., Abraxis Inc., Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, and Merck
  • Active expansion strategies are undertaken by a number of the major market entities in order to strengthen their position
  • North America dominated the industry in 2016, accounting for a 42% of total revenue
  • Presence of key participants operating in the region are involved in collaborative activities are attributive for the largest share of North America in sector revenue
Click Here For Access Full Report : https://goo.gl/j4GPQV

Friday, 23 June 2017

Digital Pathology Market Growth Is Expected To Reach USD 979.0 Million By 2025

Increasing prevalence of chronic diseases, which triggers demand for advanced diagnostics, is expected to provide growth opportunities to digital pathology market. Growing economic stability and awareness pertaining to associated benefits with the use of computer-aided diagnostics is further contributing toward the industry growth.
Technological advancements such as digital imaging, computerization, robotic light microscopy, and multiple fiberoptic communications are some of the key factors contributing toward the rising adoption of digital pathology. In addition, introduction of cloud-based technology enabling storage of digital slides coupled with secure access to pathologists is expected to serve this industry as a potential growth driver.

Digital pathology has important role in companion diagnostics and drug development pipeline, including molecular biology, biobanking, molecular tissue profiling, and tissue microarray analysis. Increasing demand for high-quality tissue samples in tissue-based biomarker research is propelling the adoption of this technology over the forecast period.
This market is expected to witness intense competition in near future owing to rising adoption of rigorous strategies by the market players to sustain competition. For instance; manufacturers of whole slide imaging systems are focused on obtaining premarket approval for diagnostic digital systems to capture more revenue share.
View summary of this report, Click Here 
Further key findings from the study suggest:
  • Whole slide imaging held the dominant share as of 2016 owing to its increased use in academic research
  • Rising implementation of whole slide image scanning in stratified medicine and tissue-based biomarker research is one of the key contributing factors for the dominance of this technology
  • Telepathology segment is expected to witness lucrative growth in the near future owing to the benefits associated with its use
  • Telepathology offers faster diagnosis and synchronizes patient data, where healthcare professionals can remotely access this information
  • Rising demand for accurate & faster diagnosis fosters the demand for static image-based systems that further contributes to the static telepathology system growth 
  • Digital pathology has wide applications in academic research owing to various benefits such as cost-effectiveness and rapid results
  • The availability of unified platforms for workflows in pathology is anticipated to boost the usage rate of computer-aided imaging technology in academic research, which is anticipated to boost the segment growth.
Click Here For Access Full Report : https://goo.gl/29rT45

Thursday, 22 June 2017

Nanoparticles - Metal & Metal Oxides Market Growth In Healthcare Is Anticipated To Reach USD 80.74 Billion By 2025

Several nanotechnologies based medicines have been put forward for approval by the FDA which is anticipated to propel growth.
Success of nanomedicine has prompted the development of enhanced nanomaterials for clinical applications with particular emphasis in therapy and diagnostics. This has resulted into the significant production of metal oxide particles that hold potential utility in human medicine.
Remarkable evolution has been made in nanoparticle based medicines for theranostic applications in disease management. Diverse metals have been used for development of medicines with a promise to optimize the efficacy of nanomedicines and to improve the current standard of medical and clinical practices.

These particles are recognized to have major applications in drug delivery, diagnostic products, biomarker discovery, and product packaging. Widespread application spectrum of these particles in maintaining human health is expected to dramatically impact the progress of this market in the coming years.
Moreover, metal oxides are observed to have significant role in cancer treatment. Nanoparticle-augmented systems enable high-concentration targeted drug delivery to cancer cells, which in turn, is expected to enhance the usage rate of metal nanoparticles for cancer treatment. Development of drug delivery strategies using nanoparticle approaches are expected to bring about changes effective for cancer treatment.
However, prolonged exposure of nanoparticles adversely affects the human health as well environment thereby restraining their adoption rate. These products are involved in autophagy, oxidative stress, lysosome dysfunction, and the activation of certain signaling pathways, thereby exhibiting toxicity for human health.
View summary of this report, Click Here 
Further key findings from the report suggest:
  • Presence of untapped potential in alumina and alumina oxide particles is anticipated to create immense opportunities
  • Aluminum oxide in combination with polymeric membranes is studied for enhancement of drug delivery owing to its high porosity property displayed in the membranes
  • This enhanced efficacy of the membrane performance by the addition of alumina nanoparticles to polymeric membranes is projected to increase its adoption
  • Approval of various nanoparticle composition and surface properties for clinical diagnostics and treatment of viral infections is anticipated drive market demand
  • In-vivo imaging dominated the market with respect to revenue share
  • Use of antibody conjugated to Au nanorods Raman spectrum with polarized, sharpened, and enhanced results can be attributed for larger revenue share
  • Oncology dominated over a decade and is projected to sustain its share over the forecast period.
  • Rising incidence of cancer and other chronic multi-drug resistant diseases pronounces the demand for these particles.
  • Aforementioned factor is anticipated to drive targeted delivery with fastest YoY growth
  • Asia Pacific is projected to showcase lucrative progress in the coming years
  • Key countries in the region are working to enhance the patient’s reach to nanotechnology-based solutions
  • Moreover, continuous support from the government bodies pertaining to initiation of new projects is expected to play crucial role for projected CAGR
  • Key players contributing in this market are Pfizer Inc., Brigham Women's Hospital (BWH), Immunolight LLC, nanoComposix, Nanobiotix, Nanospectra Biosciences, Inc, Merck KGaA, and AstraZeneca
  • These participants are investing in development of the product portfolio that can target the chronic disorders
  • Arrowhead Pharmaceuticals, Cytimmune Sciences, Inc, Nanobiotix, Celgene Corporation, Siteman Center of Cancer Nanotechnology Excellence (Washington University CCNE), and BIND Biosciences are few companies that have products in the pipeline phase.
Click Here For Access Full Report : https://goo.gl/Qp2c6R

Wednesday, 21 June 2017

Respiratory Diseases Testing Market Worth Is Expected To Reach USD 6.7 Billion By 2025

The market is driven by the rising prevalence of respiratory diseases. As per Forum of International Respiratory Societies, more than 200 million people across the globe suffered from Chronic Obstructive Pulmonary Disease (COPD) and 235 million suffered from asthma in 2014. In addition, the source stated that more than 50 million people struggle with occupational lung diseases annually. Thus, constantly growing target patient population is anticipated to drive the growth.

The adoption of innovative technologies, such as Computed Tomography (CT), for COPD diagnosis is expected to drive the growth. The other new technology in acute medical management of COPD is pulse oximeter that is used for outpatient monitoring.  Airway management plays a main role in testing and management of COPD. Also, with recent technological innovations, there has been a 12.1 % increase in the use of Noninvasive Mechanical Ventilation (NIV) for management of COPD. Along with technological advancements, use of digital radiography (X-ray) and advanced portable spirometers is gaining momentum in the market.
View summary of this report, Click Here 
Further key findings from the study suggest:
  • The growing prevalence of COPD and asthma across the globe is expected to increase the demand for respiratory disease testing devices and thereby drive the market growth
  • In products, imaging tests held the largest share in 2016 due to rapid development and adoption of innovative technologies
  • In respiratory measurement, spirometers, pulse oximeters, ventilators, capnographs, and other noninvasive ventilators used for measurement of lung capacity are expected to grow at a rate of more than 4% over the forecast period
  • In end-use, hospitals segment held the largest share in 2016 and is anticipated to grow over the forecast period
  • North America the largest market share in 2016. Growing prevalence of respiratory diseases such as COPD, asthma is increasing the demand for respiratory disease testing/diagnostic in North American countries.
  • Asia Pacific region is expected to grow at the fastest rate during the forecast period. This growth can be attributed to various factors such as improving health care infrastructure and increasing patient awareness regarding the availability of new diagnostic techniques for respiratory diseases, such as COPD & asthma.
  • Some of the major players competing in this market include, but are not limited to, Becton Dickinson (Carefusion Corporation); Koninklijke Philips N.V. (Respironics); ResMed Company; Fischer & Paykel; and Medtronic. These players are strong brands in the market as they have elaborate product portfolios in respiratory disease testing market.
Click Here For Access Full Report : https://goo.gl/3wqMw5

Tuesday, 20 June 2017

Global Glycomics/Glycobiology Market Worth Is Expected To Reach USD 2.1 Billion By 2025

Increasing investment in R&D by research institutes and pharmaceutical & biotechnology companies has been a major factor driving market growth. In addition, technological advancement has led to increased demand for advanced glycomics products for drug discovery & development, diagnostics, and oncology research. 

Escalating popularity of personalized medicines for the treatment of several severe chronic diseases and genetic disorders is another major factor contributing toward the growth. Personalized medicines involve the application of glycomics for the study of structure and function of glycans that are attached to biomolecules. Glycans play a crucial role in modulating various biological processes and their assessment can help determine the susceptibility to diseases & response to treatment. Thus, application of glycobiology products is expected to rise in near future, owing to their high potential in personalized medicine.
Untapped opportunities in developing regions, including Asia Pacific and Africa, are another major factor supporting the growth of the glycomics market. Glycomics research is important for comprehensive study of glycomes to understand the cellular signaling pathways, cell functions, genetic structure, and physiological & pathological aspects. Glycomics research has become more popular these days due to its advantages over genomic/proteomic analysis that cannot be used to study many pathological processes. Thus, the demand for advanced glycomics products by researchers and healthcare professionals is expected to fuel the sector growth.
View summary of this report, Click Here
Further Key Findings From the Report Suggest:
  • Enzymes segment is the fastest growing segment of the glycobiology market in 2016, due to its huge application in research & diagnostics and repetitive purchase of these products
  • In the application segment, drug discovery & development accounted for the largest revenue share in 2016, owing to the growing focus on novel drug development and demand for personalized medicines
  • The academic and research institutes dominated in terms of revenue in 2016, owing to the large focus on glycobiology research and proteomics study
  • The North America glycobiology market is the leading regional sector and expected to dominate the market during forecast period
  • Existence of large number of research laboratories, pharmaceutical companies, and biotechnology companies in North America region is the major reason for the high demand for glycobiology products in this region
  • The Asia Pacific glycobiology market is expected to grow at the highest growth rate during the forecast period
  • Some of the major players include Danaher; ProZyme; Shimadzu Corporation; Agilent Technologies; Bruker; Merck KGaA; Takara Bio, Inc.; New England Biolabs; ThermoFisher Scientific, Inc.; and Waters Corporation.
Click Here For Access Full Report :  https://goo.gl/2Jbzki